Related Experiment Videos
Endothelin antagonists and heart failure
David Hürlimann1, Frank Enseleit, Georg Noll
1Cardio Vascular Center, Cardiology, University Hospital, CH - 8091 Zürich, Switzerland.
Insights
New treatments targeting endothelin-1 (ET-1) show promise for chronic heart failure (CHF). Blocking ET-1 receptors improved hemodynamics and symptoms in CHF patients, offering potential for better outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Translational Medicine
Background:
- Chronic heart failure (CHF) involves impaired cardiac function and high mortality despite current treatments.
- Elevated plasma endothelin-1 (ET-1) levels in CHF correlate with disease severity and predict mortality.
- Novel therapeutic strategies are needed to address the persistent high mortality in CHF patients.
Purpose of the Study:
- To evaluate the potential of endothelin receptor antagonists in managing chronic heart failure.
- To assess the impact of ET-1 pathway inhibition on hemodynamic parameters and symptoms in CHF.
Main Methods:
- Investigated combined ET(A/B) and selective ET(A) receptor antagonists in CHF patients.
- Monitored hemodynamic improvements and symptom changes following antagonist administration.
Main Results:
- Endothelin receptor antagonists demonstrated significant hemodynamic improvements in patients with CHF.
- These agents showed potential in alleviating symptoms associated with chronic heart failure.
Conclusions:
- Endothelin receptor antagonists represent a promising therapeutic approach for CHF.
- Targeting the ET-1 pathway may improve hemodynamics, symptoms, and potentially the prognosis of patients with chronic heart failure.
Abstract:
Chronic heart failure (CHF) is characterized by impaired left ventricular function, increased peripheral and pulmonary vascular resistance, reduced exercise tolerance, and dyspnea. Despite considerable progress in the treatment of CHF, especially in targeting activated neurohumoral systems, mortality in these patients remains high. Therefore, new treatment approaches are warranted. Endothelin-1 (ET-1) plasma levels are elevated in CHF and correlate with both hemodynamic severity and symptoms. Plasma levels of ET-1 are strong independent predictors of mortality in CHF. Combined ET(A/B) selective ET(A) receptor antagonists have been evaluated in patients with CHF showing impressive hemodynamic improvements. These results indicate that ET receptor antagonists indeed have a potential to improve hemodynamics, symptoms, and potentially prognosis in patients with CHF, which still carries a high mortality.